Licensable university IP
Crispr-based FOXP3 gene engineered t cells and hematopoietic stem cell precursors to treat IPEX syndrome patients
Crispr-based FOXP3 gene engineered t cells and hematopoietic stem cell precursors to treat IPEX syndrome patients is marketed for licensing by Stanford University (OTL). It is documented in US patent US 12,540,311. The current assignee of record is Board Of Trustees Of Leland Stanford Junior University Stanford California. Google Patents reports its legal status as “Active” (an automated indicator, not a legal determination). Its expected expiration is 2043-03-26.
Patent picture
| Field | Value | Reliability | Source |
|---|---|---|---|
| US patent | US 12,540,311 | High | Google Patents |
| Patent title | Crispr-based FOXP3 gene engineered t cells and hematopoietic stem cell precursors to treat IPEX syndrome patients | High | Google Patents |
| Current assignee | Board Of Trustees Of Leland Stanford Junior University Stanford California | Good | Google Patents |
| Original assignee | Board Of Trustees Of Leland Stanford Junior University Stanford California | Good | Google Patents |
| Legal status | Active | Moderate | Google Patents |
| Filing date | 2021-02-13 | High | Google Patents |
| Priority date | 2020-02-13 | High | Google Patents |
| Publication date | 2026-02-03 | High | Google Patents |
| Expected expiration | 2043-03-26 | Moderate | Google Patents |
- High 90% and up
- Good 80 to 89%
- Moderate 70 to 79%
Legal status is Google Patents' automated indicator, not a legal determination.
Joined to US 12,540,311 by its printed patent number (a deterministic match), then enriched from public Google Patents data. Fields are shown only where resolved against a public source; unresolved fields are omitted, never guessed.
Grouped under Biotechnology & Life Sciences, derived from its patent classification (CPC A61K, C12N; Google Patents).
Original listing
This technology is marketed for licensing by Stanford University (OTL). View the original listing.